Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform recommendation. As of February 19, 2025, the average one-year price ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (LSE:0A4C) with a Market Perform recommendation. There are 326 funds or institutions reporting positions in ...

William Blair started coverage on shares of Altimmune in a research note on Friday. They issued a “market perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $ ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

William Blair analyst S. Zackfia now forecasts that the company will post earnings of $0.27 per share for the quarter, […] Skip to main content Analyst Ratings ...

On Friday, William Blair reaffirmed its positive stance on CyberArk Software (NASDAQ:CYBR), maintaining an Outperform rating. The firm's analyst, Jonathan Ho, provided insights into the company's ...

Despite this, William Blair maintained an Underperform rating on the stock. Palantir's financial outlook for 2025 anticipates revenues of $3.75 billion, which is above the consensus estimate of $3 ...